Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10...

FDA Recall #D-0291-2025 — Class II — March 7, 2025

Recall #D-0291-2025 Date: March 7, 2025 Classification: Class II Status: Ongoing

Product Description

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-443-20.

Reason for Recall

Super-Potent Drug: Out of specification potency results were obtained.

Recalling Firm

Mylan Institutional, Inc. — Rockford, IL

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

1,068 cartons

Distribution

Nationwide in the USA

Code Information

Lot 3115773, Exp. 03/31/2025

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated